Pan-cancer analysis reveals correlation between RAB3B expression and tumor heterogeneity, immune microenvironment, and prognosis in multiple cancers

RAB3B is essential for the transportation and secretion within cells. Its increased expression is linked to the development and progression of various malignancies. However, understanding of RAB3B’s involvement in carcinogenesis is mostly limited to specific cancer subtypes. Hence, exploring RAB3B&#...

Full description

Saved in:
Bibliographic Details
Published inScientific reports Vol. 14; no. 1; pp. 9881 - 17
Main Authors Liu, Xu-Sheng, Chen, Ya-Lan, Chen, Yu-Xuan, Wu, Rui-Min, Tan, Fan, Wang, Ya-Lan, Liu, Zi-Yue, Gao, Yan, Pei, Zhi-Jun
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 30.04.2024
Nature Publishing Group
Nature Portfolio
Subjects
Online AccessGet full text

Cover

Loading…
Abstract RAB3B is essential for the transportation and secretion within cells. Its increased expression is linked to the development and progression of various malignancies. However, understanding of RAB3B’s involvement in carcinogenesis is mostly limited to specific cancer subtypes. Hence, exploring RAB3B's regulatory roles and molecular mechanisms through comprehensive cancer datasets might offer innovative approaches for managing clinical cancer. To examine the potential involvement of RAB3B in the development of cancer, we analyzed data from various sources including The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression Project (GTEx), cBioPortal, HPA, UALCAN, and tissue microarray (TAM). Using bioinformatics techniques, we examined the correlation between RAB3B expression and prognosis, tumor heterogeneity, methylation modifications, and immune microenvironment across different cancer types. Our findings indicate that elevated RAB3B expression can independently predict prognosis in many tumors and has moderate accuracy for diagnosing most cancers. In most cancer types, we identified RAB3B mutations that showed a significant correlation with tumor mutational burden (TMB), mutant-allele tumor heterogeneity (MATH), and microsatellite instability (MSI). Abnormal DNA methylation patterns were also observed in most cancers compared to normal tissues. Additionally, we found significant correlations between RAB3B expression, immune cell infiltration, and immune scores across various cancers. Through pan-cancer analysis, we observed significant differences in RAB3B expression levels between tumors and normal tissues, making it a potential primary factor for cancer diagnosis and prognosis. The IHC results revealed that the expression of RAB3B in six types of tumors was consistent with the results of the pan-cancer analysis of the database. Furthermore, RAB3B showed potential associations with tumor heterogeneity and immunity. Thus, RAB3B can be utilized as an auxiliary diagnostic marker for early tumor detection and a prognostic biomarker for various tumor types.
AbstractList RAB3B is essential for the transportation and secretion within cells. Its increased expression is linked to the development and progression of various malignancies. However, understanding of RAB3B's involvement in carcinogenesis is mostly limited to specific cancer subtypes. Hence, exploring RAB3B's regulatory roles and molecular mechanisms through comprehensive cancer datasets might offer innovative approaches for managing clinical cancer. To examine the potential involvement of RAB3B in the development of cancer, we analyzed data from various sources including The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression Project (GTEx), cBioPortal, HPA, UALCAN, and tissue microarray (TAM). Using bioinformatics techniques, we examined the correlation between RAB3B expression and prognosis, tumor heterogeneity, methylation modifications, and immune microenvironment across different cancer types. Our findings indicate that elevated RAB3B expression can independently predict prognosis in many tumors and has moderate accuracy for diagnosing most cancers. In most cancer types, we identified RAB3B mutations that showed a significant correlation with tumor mutational burden (TMB), mutant-allele tumor heterogeneity (MATH), and microsatellite instability (MSI). Abnormal DNA methylation patterns were also observed in most cancers compared to normal tissues. Additionally, we found significant correlations between RAB3B expression, immune cell infiltration, and immune scores across various cancers. Through pan-cancer analysis, we observed significant differences in RAB3B expression levels between tumors and normal tissues, making it a potential primary factor for cancer diagnosis and prognosis. The IHC results revealed that the expression of RAB3B in six types of tumors was consistent with the results of the pan-cancer analysis of the database. Furthermore, RAB3B showed potential associations with tumor heterogeneity and immunity. Thus, RAB3B can be utilized as an auxiliary diagnostic marker for early tumor detection and a prognostic biomarker for various tumor types.RAB3B is essential for the transportation and secretion within cells. Its increased expression is linked to the development and progression of various malignancies. However, understanding of RAB3B's involvement in carcinogenesis is mostly limited to specific cancer subtypes. Hence, exploring RAB3B's regulatory roles and molecular mechanisms through comprehensive cancer datasets might offer innovative approaches for managing clinical cancer. To examine the potential involvement of RAB3B in the development of cancer, we analyzed data from various sources including The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression Project (GTEx), cBioPortal, HPA, UALCAN, and tissue microarray (TAM). Using bioinformatics techniques, we examined the correlation between RAB3B expression and prognosis, tumor heterogeneity, methylation modifications, and immune microenvironment across different cancer types. Our findings indicate that elevated RAB3B expression can independently predict prognosis in many tumors and has moderate accuracy for diagnosing most cancers. In most cancer types, we identified RAB3B mutations that showed a significant correlation with tumor mutational burden (TMB), mutant-allele tumor heterogeneity (MATH), and microsatellite instability (MSI). Abnormal DNA methylation patterns were also observed in most cancers compared to normal tissues. Additionally, we found significant correlations between RAB3B expression, immune cell infiltration, and immune scores across various cancers. Through pan-cancer analysis, we observed significant differences in RAB3B expression levels between tumors and normal tissues, making it a potential primary factor for cancer diagnosis and prognosis. The IHC results revealed that the expression of RAB3B in six types of tumors was consistent with the results of the pan-cancer analysis of the database. Furthermore, RAB3B showed potential associations with tumor heterogeneity and immunity. Thus, RAB3B can be utilized as an auxiliary diagnostic marker for early tumor detection and a prognostic biomarker for various tumor types.
RAB3B is essential for the transportation and secretion within cells. Its increased expression is linked to the development and progression of various malignancies. However, understanding of RAB3B’s involvement in carcinogenesis is mostly limited to specific cancer subtypes. Hence, exploring RAB3B's regulatory roles and molecular mechanisms through comprehensive cancer datasets might offer innovative approaches for managing clinical cancer. To examine the potential involvement of RAB3B in the development of cancer, we analyzed data from various sources including The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression Project (GTEx), cBioPortal, HPA, UALCAN, and tissue microarray (TAM). Using bioinformatics techniques, we examined the correlation between RAB3B expression and prognosis, tumor heterogeneity, methylation modifications, and immune microenvironment across different cancer types. Our findings indicate that elevated RAB3B expression can independently predict prognosis in many tumors and has moderate accuracy for diagnosing most cancers. In most cancer types, we identified RAB3B mutations that showed a significant correlation with tumor mutational burden (TMB), mutant-allele tumor heterogeneity (MATH), and microsatellite instability (MSI). Abnormal DNA methylation patterns were also observed in most cancers compared to normal tissues. Additionally, we found significant correlations between RAB3B expression, immune cell infiltration, and immune scores across various cancers. Through pan-cancer analysis, we observed significant differences in RAB3B expression levels between tumors and normal tissues, making it a potential primary factor for cancer diagnosis and prognosis. The IHC results revealed that the expression of RAB3B in six types of tumors was consistent with the results of the pan-cancer analysis of the database. Furthermore, RAB3B showed potential associations with tumor heterogeneity and immunity. Thus, RAB3B can be utilized as an auxiliary diagnostic marker for early tumor detection and a prognostic biomarker for various tumor types.
Abstract RAB3B is essential for the transportation and secretion within cells. Its increased expression is linked to the development and progression of various malignancies. However, understanding of RAB3B’s involvement in carcinogenesis is mostly limited to specific cancer subtypes. Hence, exploring RAB3B's regulatory roles and molecular mechanisms through comprehensive cancer datasets might offer innovative approaches for managing clinical cancer. To examine the potential involvement of RAB3B in the development of cancer, we analyzed data from various sources including The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression Project (GTEx), cBioPortal, HPA, UALCAN, and tissue microarray (TAM). Using bioinformatics techniques, we examined the correlation between RAB3B expression and prognosis, tumor heterogeneity, methylation modifications, and immune microenvironment across different cancer types. Our findings indicate that elevated RAB3B expression can independently predict prognosis in many tumors and has moderate accuracy for diagnosing most cancers. In most cancer types, we identified RAB3B mutations that showed a significant correlation with tumor mutational burden (TMB), mutant-allele tumor heterogeneity (MATH), and microsatellite instability (MSI). Abnormal DNA methylation patterns were also observed in most cancers compared to normal tissues. Additionally, we found significant correlations between RAB3B expression, immune cell infiltration, and immune scores across various cancers. Through pan-cancer analysis, we observed significant differences in RAB3B expression levels between tumors and normal tissues, making it a potential primary factor for cancer diagnosis and prognosis. The IHC results revealed that the expression of RAB3B in six types of tumors was consistent with the results of the pan-cancer analysis of the database. Furthermore, RAB3B showed potential associations with tumor heterogeneity and immunity. Thus, RAB3B can be utilized as an auxiliary diagnostic marker for early tumor detection and a prognostic biomarker for various tumor types.
ArticleNumber 9881
Author Liu, Zi-Yue
Tan, Fan
Chen, Yu-Xuan
Pei, Zhi-Jun
Liu, Xu-Sheng
Gao, Yan
Chen, Ya-Lan
Wu, Rui-Min
Wang, Ya-Lan
Author_xml – sequence: 1
  givenname: Xu-Sheng
  surname: Liu
  fullname: Liu, Xu-Sheng
  organization: Department of Nuclear Medicine, Hubei Provincial Clinical Research Center for Precision Diagnosis and Treatment of Liver Cancer, Taihe Hospital, Hubei University of Medicine, Hubei Provincial Clinical Research Center for Umbilical Cord Blood Hematopoietic Stem Cells, Taihe Hospital, Hubei University of Medicine, Hubei Key Laboratory of Embryonic Stem Cell Research
– sequence: 2
  givenname: Ya-Lan
  surname: Chen
  fullname: Chen, Ya-Lan
  organization: Department of Gastroenterology, The Affiliated Hospital of Hebei University
– sequence: 3
  givenname: Yu-Xuan
  surname: Chen
  fullname: Chen, Yu-Xuan
  organization: Department of Nuclear Medicine, Hubei Provincial Clinical Research Center for Precision Diagnosis and Treatment of Liver Cancer, Taihe Hospital, Hubei University of Medicine
– sequence: 4
  givenname: Rui-Min
  surname: Wu
  fullname: Wu, Rui-Min
  organization: Department of Nuclear Medicine, Hubei Provincial Clinical Research Center for Precision Diagnosis and Treatment of Liver Cancer, Taihe Hospital, Hubei University of Medicine
– sequence: 5
  givenname: Fan
  surname: Tan
  fullname: Tan, Fan
  organization: Department of Nuclear Medicine, Hubei Provincial Clinical Research Center for Precision Diagnosis and Treatment of Liver Cancer, Taihe Hospital, Hubei University of Medicine
– sequence: 6
  givenname: Ya-Lan
  surname: Wang
  fullname: Wang, Ya-Lan
  organization: Department of Nuclear Medicine, Hubei Provincial Clinical Research Center for Precision Diagnosis and Treatment of Liver Cancer, Taihe Hospital, Hubei University of Medicine
– sequence: 7
  givenname: Zi-Yue
  surname: Liu
  fullname: Liu, Zi-Yue
  organization: Department of Nuclear Medicine, Hubei Provincial Clinical Research Center for Precision Diagnosis and Treatment of Liver Cancer, Taihe Hospital, Hubei University of Medicine
– sequence: 8
  givenname: Yan
  surname: Gao
  fullname: Gao, Yan
  organization: Department of Nuclear Medicine, Hubei Provincial Clinical Research Center for Precision Diagnosis and Treatment of Liver Cancer, Taihe Hospital, Hubei University of Medicine
– sequence: 9
  givenname: Zhi-Jun
  surname: Pei
  fullname: Pei, Zhi-Jun
  email: pzjzml1980@taihehospital.com
  organization: Department of Nuclear Medicine, Hubei Provincial Clinical Research Center for Precision Diagnosis and Treatment of Liver Cancer, Taihe Hospital, Hubei University of Medicine, Hubei Provincial Clinical Research Center for Umbilical Cord Blood Hematopoietic Stem Cells, Taihe Hospital, Hubei University of Medicine, Hubei Key Laboratory of Embryonic Stem Cell Research
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38688977$$D View this record in MEDLINE/PubMed
BookMark eNp9UstuFDEQHKEgEpb8AAdkiUsOGfBjHvYJJRGPSJFACM6W7enZOJqxF9uz7P4HH4x3J4Qkh_hiq7uquttdL4sD5x0UxWuC3xHM-PtYkVrwEtOqbHDNSbl5VhxRXNUlZZQe3HsfFscx3uB8aioqIl4Uh4w3nIu2PSr-fFOuNMoZCEg5NWyjjSjAGtQQkfEhwKCS9Q5pSL8BHPp-ds7OEWxWAWLcJZTrUJpGH9A1JAh-CQ5s2p4iO46TAzRaEzy4tQ3ejeDS6Z6xykDnd8WsQ-M0JLsaAM2NxFfF8z7Xh-Pbe1H8_PTxx8WX8urr58uLs6vS1BVJpaCc1lCThnGtddezTlR93RrOWsJ12xtF2hxRGoRgAhqma8Y57luNO93rii2Ky1m38-pGroIdVdhKr6zcB3xYShWSNQNIVYPQgmKTf70CJTRuQIBoRS8wNd1O68OstZr0CJ3JkwY1PBB9mHH2Wi79WhKCG0JonRVObhWC_zVBTHK00cAwKAd-ipLhSrR5q5xk6NtH0Bs_hby-GYU54XnkRfHmfkt3vfzbfgbQGZA3FGOA_g5CsNy5TM4uk9llcu8yuckk_ohkbNp7JI9lh6epbKbGXMctIfxv-wnWXyxA6sE
CitedBy_id crossref_primary_10_1007_s12672_024_01236_1
crossref_primary_10_1186_s40001_025_02407_8
Cites_doi 10.1101/cshperspect.a019505
10.3390/cells10020223
10.1186/s41065-023-00290-z
10.7150/thno.48954
10.3389/fimmu.2023.1058627
10.1038/nrclinonc.2016.15
10.1016/j.cell.2018.03.022
10.3389/fonc.2022.798531
10.1017/S0029665118000150
10.1088/1361-6560/aab4b1
10.1038/nrc.2016.36
10.3389/fimmu.2021.687975
10.32604/oncologie.2022.026118
10.1002/cam4.3647
10.32604/biocell.2023.031568
10.1016/j.esmoop.2021.100124
10.1016/j.annonc.2022.08.084
10.1038/nbt.3772
10.5114/wo.2014.47136
10.1038/srep41404
10.1158/0008-5472.CAN-17-0307
10.1038/nature24277
10.7717/peerj.9624
10.1200/PO.17.00073
10.1097/JTO.0b013e3181ec173d
10.1016/j.immuni.2018.03.023
10.3322/caac.21660
10.1007/s10549-017-4113-z
10.3389/fphar.2022.1010879
10.3390/cimb45070386
10.1038/ncomms3612
10.3390/ijms21114012
10.1186/s12885-022-09370-1
10.1186/1479-5876-12-17
10.1038/nature12213
10.1186/s12943-021-01428-1
10.1038/s43018-021-00250-4
10.23812/j.biol.regul.homeost.agents.20223604.94
10.1038/nrg2005
10.1016/j.ejps.2016.09.023
10.3390/cancers13030558
10.1126/scisignal.2004088
10.1007/s10555-020-09952-0
10.1007/s12032-014-0859-x
10.1186/s12957-020-02084-3
10.3390/cells8080909
10.1126/science.1260419
10.1016/j.immuni.2021.01.012
10.1002/jcb.29948
10.1007/s13277-015-3938-5
10.1128/MCB.05958-11
10.1158/2159-8290.CD-12-0095
10.23812/j.biol.regul.homeost.agents.20243803.186
10.32604/biocell.2023.025157
10.3389/fimmu.2021.724741
10.1006/bbrc.1997.7039
10.6004/jnccn.2019.7307
10.32604/biocell.2023.027209
10.1016/j.stem.2021.04.011
10.1016/j.neo.2017.05.002
10.1111/cas.14210
10.2174/1381612826666200917145228
10.1158/1538-7445.AM2022-3912
10.3389/fmolb.2022.962743
10.3390/cancers15061685
10.1038/nrm2728
10.3389/fcell.2020.603516
10.23812/j.biol.regul.homeost.agents.20233702.64
10.1038/s12276-018-0191-1
10.3389/fonc.2023.1097015
ContentType Journal Article
Copyright The Author(s) 2024
2024. The Author(s).
The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2024
– notice: 2024. The Author(s).
– notice: The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88A
88E
88I
8FE
8FH
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M1P
M2P
M7P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
Q9U
7X8
5PM
DOA
DOI 10.1038/s41598-024-60581-x
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Biology Database (Alumni Edition)
Medical Database (Alumni Edition)
Science Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
ProQuest Health & Medical Collection
Medical Database
Science Database
Biological Science Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Biology Journals (Alumni Edition)
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Science Journals
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic



MEDLINE
Publicly Available Content Database
CrossRef
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 5
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2045-2322
EndPage 17
ExternalDocumentID oai_doaj_org_article_a5e9b920c1594ea9b06e9e979f902cd4
PMC11061125
38688977
10_1038_s41598_024_60581_x
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID 0R~
3V.
4.4
53G
5VS
7X7
88A
88E
88I
8FE
8FH
8FI
8FJ
AAFWJ
AAJSJ
AAKDD
ABDBF
ABUWG
ACGFS
ACSMW
ACUHS
ADBBV
ADRAZ
AENEX
AEUYN
AFKRA
AJTQC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
C6C
CCPQU
DIK
DWQXO
EBD
EBLON
EBS
ESX
FYUFA
GNUQQ
GROUPED_DOAJ
GX1
HCIFZ
HH5
HMCUK
HYE
KQ8
LK8
M0L
M1P
M2P
M48
M7P
M~E
NAO
OK1
PIMPY
PQQKQ
PROAC
PSQYO
RNT
RNTTT
RPM
SNYQT
UKHRP
AASML
AAYXX
AFPKN
CITATION
PHGZM
PHGZT
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
PQGLB
7XB
8FK
AARCD
K9.
PKEHL
PQEST
PQUKI
Q9U
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c541t-92825e51638bbbdf3d94f57c83718b7fca1794fabe9939e63b53880f7b0dbfb43
IEDL.DBID M48
ISSN 2045-2322
IngestDate Wed Aug 27 01:22:23 EDT 2025
Thu Aug 21 18:34:29 EDT 2025
Mon Jul 21 09:58:33 EDT 2025
Wed Aug 13 05:16:37 EDT 2025
Mon Jul 21 06:01:00 EDT 2025
Tue Jul 01 01:01:31 EDT 2025
Thu Apr 24 22:51:40 EDT 2025
Fri Feb 21 02:40:12 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords RAB3B
Prognosis
Diagnosis
Pan-cancer
Immune infiltration
Language English
License 2024. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c541t-92825e51638bbbdf3d94f57c83718b7fca1794fabe9939e63b53880f7b0dbfb43
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1038/s41598-024-60581-x
PMID 38688977
PQID 3049081899
PQPubID 2041939
PageCount 17
ParticipantIDs doaj_primary_oai_doaj_org_article_a5e9b920c1594ea9b06e9e979f902cd4
pubmedcentral_primary_oai_pubmedcentral_nih_gov_11061125
proquest_miscellaneous_3049720481
proquest_journals_3049081899
pubmed_primary_38688977
crossref_primary_10_1038_s41598_024_60581_x
crossref_citationtrail_10_1038_s41598_024_60581_x
springer_journals_10_1038_s41598_024_60581_x
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2024-04-30
PublicationDateYYYYMMDD 2024-04-30
PublicationDate_xml – month: 04
  year: 2024
  text: 2024-04-30
  day: 30
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Scientific reports
PublicationTitleAbbrev Sci Rep
PublicationTitleAlternate Sci Rep
PublicationYear 2024
Publisher Nature Publishing Group UK
Nature Publishing Group
Nature Portfolio
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
– name: Nature Portfolio
References Hoadley, Yau, Hinoue, Wolf, Lazar, Drill, Shen, Taylor, Cherniack, Thorsson (CR2) 2018; 173
Ye, Tang, Liu, Xie, Wu, Liu, Chen, Xie (CR27) 2014; 12
Wang, Qian, Du, Sanchez-Solana, Chen, Park, Chen, Jenkins, Luo, Tripathi (CR39) 2022
Yoshihara, Shahmoradgoli, Martínez, Vegesna, Kim, Torres-Garcia, Treviño, Shen, Laird, Levine (CR51) 2013; 4
Fayad, Eid, Abdulsahib, Zaki, Binjawhar, Alshaya, Altalhi, Alsharif, Elwishahy, El-shaer (CR60) 2024; 38
Bareche, Kelly, Abbas-Aghababazadeh, Nakano, Esfahani, Tkachuk, Mohammad, Samstein, Lee, Morris (CR69) 2022; 33
Zhang, Min, Zhang, Ma, Yang, Shou (CR30) 2016; 37
Darvin, Toor, Sasidharan Nair, Elkord (CR20) 2018; 50
Mandrekar (CR64) 2010; 5
Vivian, Rao, Nothaft, Ketchum, Armstrong, Novak, Pfeil, Narkizian, Deran, Musselman-Brown (CR38) 2017; 35
Chandrashekar, Bashel, Balasubramanya, Creighton, Ponce-Rodriguez, Chakravarthi, Varambally (CR47) 2017; 19
Liu, Zhou, Yuan, Gao, Kui, Liu, Pei (CR18) 2021
Li, Lv, Zhang, Zhu, Guo, Wang, Huang, Chen, Zhang, Li (CR59) 2024; 48
Luo, Liu, Yuan, Huang, Diao (CR25) 2021; 27
Ozga, Chow, Luster (CR3) 2021; 54
Kottorou, Dimitrakopoulos, Diamantopoulou, Kalofonou, Stavropoulos, Thomopoulos, Makatsoris, Koutras, Kalofonos (CR35) 2023; 15
Lordick, Janjigian (CR54) 2016; 13
Tomczak, Czerwińska, Wiznerowicz (CR36) 2015; 1A
Galvano, Gristina, Malapelle, Pisapia, Pepe, Barraco, Castiglia, Perez, Rolfo, Troncone (CR67) 2021
Dai, Sun, Wei, Xi (CR41) 2023; 45
Raffaniello (CR24) 2021; 122
Morgan, Davies, Mc Auley (CR68) 2018; 77
Tan, Chang, Chng, Wansa, Sung, Cheung (CR26) 2012; 32
Rizzo, Ricci, Brandi (CR10) 2021; 13
Cheng, Sokolova, Schaeffer, Small, Higano (CR8) 2019; 17
Lawrence, Stojanov, Polak, Kryukov, Cibulskis, Sivachenko, Carter, Stewart, Mermel, Roberts (CR66) 2013; 499
Bonneville, Krook, Kautto, Miya, Wing, Chen, Reeser, Yu, Roychowdhury (CR46) 2017
Wang, Li, Jia, Kim, Li, Deng, Zhang, Krebsbach, Wang (CR70) 2021; 28
Tsunedomi, Yoshimura, Kimura, Nishiyama, Fujiwara, Matsukuma, Kanekiyo, Matsui, Shindo, Watanabe (CR29) 2022; 22
Han, Liu, Ye, Tian, Ji (CR65) 2020; 18
Wang, Gong, Cao (CR43) 2023; 160
Zhong, Shi, Wen, Chen, Li, Ruan, Zeng, Dai, Xiong, Li (CR4) 2023; 14
Topalian, Taube, Anders, Pardoll (CR19) 2016; 16
Wang, Skotland, Berge, Sandvig, Llorente (CR32) 2017; 98
Gu, Wang, Wang, Ma (CR22) 2023; 13
Raufaste-Cazavieille, Santiago, Droit (CR55) 2022
Machlowska, Baj, Sitarz, Maciejewski, Sitarz (CR53) 2020; 21
Khan, Liu, Yan, Tahir, Ali, Huang (CR9) 2021; 40
Li, Zou, Cai, Li, Yang, Zhang, Chen, Zhu (CR33) 2022
Dai, Zhu, Liu, Xu, Ge, Jiang, Yang, Li, Wang, Wu (CR42) 2017; 7
Chen, Shan, Li (CR7) 2023; 37
Ma, Jiang, Liu, Liu, Shao (CR11) 2017; 162
Battle (CR37) 2017; 550
Dieci, Miglietta, Guarneri (CR15) 2021; 10
Klengel, Piiper, Pittelkow, Zeuzem (CR28) 1997; 236
Xiao, Jiang, Chen, Huang, Wei (CR16) 2022; 24
Liu, Liu, Zeng, Zeng, Chen, Tan, Gao, Liu, Zhang, Zhang (CR17) 2022; 13
Uhlén, Fagerberg, Hallström, Lindskog, Oksvold, Mardinoglu, Sivertsson, Kampf, Sjöstedt, Asplund (CR40) 2015
Liu, Tang, Liu, Liao, Li, Zhao, Yuan, Jiang (CR31) 2014; 31
Li, Fan, Wang, Traugh, Chen, Liu, Li, Liu (CR48) 2017; 77
Stenmark (CR61) 2009; 10
He, Wang, Liu, Qin, Wan, Li, Ping (CR52) 2021; 10
Cerami, Gao, Dogrusoz, Gross, Sumer, Aksoy, Jacobsen, Byrne, Heuer, Larsson (CR44) 2012; 2
Zeng, Xie, Gong (CR34) 2020
Obuchowski, Bullen (CR63) 2018
Guadagno, Progida (CR23) 2019; 8
Mao, Xu, Wang, Liang, Hua, Liu, Zhang, Meng, Yu, Shi (CR14) 2021; 20
Li, Liu, Yao, Xu, Zeng, Ge, Sheng, Zhang, Zhou, Long (CR58) 2023; 47
Esteller (CR12) 2007; 8
Na, Choi, Oh, Kim, Lee, Jung, Koh, Park, Lee, Jeon (CR21) 2020; 10
Zeng, Ye, Shen, Yu, Wu, Xiong, Zhou, Qiu, Huang, Sun (CR49) 2021
Korenjak, Zavadil (CR56) 2019; 110
Chen, Wendl, Wyczalkowski, Bailey, Li, Ding (CR57) 2021; 2
Ma, Pu, Wang, Gu, Gao, Wang, Cui, Chen (CR5) 2022; 36
Baylin, Jones (CR13) 2016
Thorsson, Gibbs, Brown, Wolf, Bortone, Ou Yang, Porta-Pardo, Gao, Plaisier, Eddy (CR50) 2018; 48
Sung, Ferlay, Siegel, Laversanne, Soerjomataram, Jemal, Bray (CR1) 2021; 71
Xu, Song, Wang, Fu, Han (CR62) 2020
Gao, Aksoy, Dogrusoz, Dresdner, Gross, Sumer, Sun, Jacobsen, Sinha, Larsson (CR45) 2013
Jiang, He, Wang, Liu, Li, He, Cai (CR6) 2022; 47
K Yoshihara (60581_CR51) 2013; 4
Y Wang (60581_CR43) 2023; 160
X Jiang (60581_CR6) 2022; 47
C Zhang (60581_CR30) 2016; 37
V Thorsson (60581_CR50) 2018; 48
V Raufaste-Cazavieille (60581_CR55) 2022
D Wang (60581_CR39) 2022
X Mao (60581_CR14) 2021; 20
M Esteller (60581_CR12) 2007; 8
Y Han (60581_CR65) 2020; 18
T Xu (60581_CR62) 2020
S Li (60581_CR58) 2023; 47
E Fayad (60581_CR60) 2024; 38
PY Tan (60581_CR26) 2012; 32
D Ma (60581_CR11) 2017; 162
K Tomczak (60581_CR36) 2015; 1A
MV Dieci (60581_CR15) 2021; 10
P Darvin (60581_CR20) 2018; 50
AA Khan (60581_CR9) 2021; 40
F Lordick (60581_CR54) 2016; 13
G Dai (60581_CR41) 2023; 45
J Gu (60581_CR22) 2023; 13
D Zeng (60581_CR49) 2021
Q Luo (60581_CR25) 2021; 27
E Cerami (60581_CR44) 2012; 2
A Kottorou (60581_CR35) 2023; 15
JN Mandrekar (60581_CR64) 2010; 5
MS Lawrence (60581_CR66) 2013; 499
HH Cheng (60581_CR8) 2019; 17
J Vivian (60581_CR38) 2017; 35
L Wang (60581_CR32) 2017; 98
RD Raffaniello (60581_CR24) 2021; 122
KJ Na (60581_CR21) 2020; 10
KA Hoadley (60581_CR2) 2018; 173
R Klengel (60581_CR28) 1997; 236
F He (60581_CR52) 2021; 10
A Battle (60581_CR37) 2017; 550
DS Chandrashekar (60581_CR47) 2017; 19
T Li (60581_CR48) 2017; 77
Z Zeng (60581_CR34) 2020
M Uhlén (60581_CR40) 2015
A Galvano (60581_CR67) 2021
M Dai (60581_CR42) 2017; 7
C Ma (60581_CR5) 2022; 36
AE Morgan (60581_CR68) 2018; 77
J Gao (60581_CR45) 2013
AJ Ozga (60581_CR3) 2021; 54
F Ye (60581_CR27) 2014; 12
Z Li (60581_CR59) 2024; 48
C Wang (60581_CR70) 2021; 28
H Sung (60581_CR1) 2021; 71
J Machlowska (60581_CR53) 2020; 21
Y Bareche (60581_CR69) 2022; 33
Q Liu (60581_CR31) 2014; 31
H Stenmark (60581_CR61) 2009; 10
R Bonneville (60581_CR46) 2017
NA Obuchowski (60581_CR63) 2018
R Tsunedomi (60581_CR29) 2022; 22
H Zhong (60581_CR4) 2023; 14
SB Baylin (60581_CR13) 2016
NA Guadagno (60581_CR23) 2019; 8
M Korenjak (60581_CR56) 2019; 110
C Li (60581_CR33) 2022
Y Xiao (60581_CR16) 2022; 24
X-S Liu (60581_CR18) 2021
SL Topalian (60581_CR19) 2016; 16
F Chen (60581_CR57) 2021; 2
A Rizzo (60581_CR10) 2021; 13
X-S Liu (60581_CR17) 2022; 13
W Chen (60581_CR7) 2023; 37
References_xml – year: 2016
  ident: CR13
  article-title: Epigenetic Determinants of Cancer
  publication-title: Cold Spring Harbor Perspect Biol.
  doi: 10.1101/cshperspect.a019505
– volume: 10
  start-page: 223
  year: 2021
  ident: CR15
  article-title: Immune infiltrates in breast cancer: recent updates and clinical implications
  publication-title: Cells
  doi: 10.3390/cells10020223
– volume: 160
  start-page: 26
  year: 2023
  ident: CR43
  article-title: LncRNA WAC-AS1 expression in human tumors correlates with immune infiltration and affects prognosis
  publication-title: Hereditas
  doi: 10.1186/s41065-023-00290-z
– volume: 10
  start-page: 9579
  year: 2020
  end-page: 9590
  ident: CR21
  article-title: Reciprocal change in Glucose metabolism of Cancer and Immune Cells mediated by different Glucose Transporters predicts Immunotherapy response
  publication-title: Theranostics
  doi: 10.7150/thno.48954
– volume: 14
  start-page: 1058627
  year: 2023
  ident: CR4
  article-title: Pan-cancer analysis reveals potential of FAM110A as a prognostic and immunological biomarker in human cancer
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2023.1058627
– volume: 13
  start-page: 348
  year: 2016
  end-page: 360
  ident: CR54
  article-title: Clinical impact of tumour biology in the management of gastroesophageal cancer
  publication-title: Nat. Rev. Clin. Oncol.
  doi: 10.1038/nrclinonc.2016.15
– volume: 173
  start-page: 291
  year: 2018
  end-page: 304.e6
  ident: CR2
  article-title: Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer
  publication-title: Cell
  doi: 10.1016/j.cell.2018.03.022
– year: 2022
  ident: CR33
  article-title: Comprehensive expression profile analysis of neutrophil extracellular trap-affected genes in gastric cancer cells and the clinical significance of lncRNA NEAT1-related signaling
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2022.798531
– volume: 77
  start-page: 412
  year: 2018
  end-page: 422
  ident: CR68
  article-title: The role of DNA methylation in ageing and cancer
  publication-title: Proc. Nutr. Soc.
  doi: 10.1017/S0029665118000150
– year: 2018
  ident: CR63
  article-title: Receiver operating characteristic (ROC) curves: review of methods with applications in diagnostic medicine
  publication-title: Phys. Med. Biol.
  doi: 10.1088/1361-6560/aab4b1
– volume: 16
  start-page: 275
  year: 2016
  end-page: 287
  ident: CR19
  article-title: Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc.2016.36
– year: 2021
  ident: CR49
  article-title: IOBR: Multi-omics immuno-oncology biological research to decode tumor microenvironment and signatures
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2021.687975
– volume: 24
  start-page: 729
  year: 2022
  end-page: 742
  ident: CR16
  article-title: PD-1 relevant genes predict the prognosis of breast cancer and their prediction effect in tumor response to immunotherapy
  publication-title: Oncologie
  doi: 10.32604/oncologie.2022.026118
– volume: 10
  start-page: 1839
  year: 2021
  end-page: 1847
  ident: CR52
  article-title: Esophageal cancer: Trends in incidence and mortality in China from 2005 to 2015
  publication-title: Cancer Med.
  doi: 10.1002/cam4.3647
– volume: 48
  start-page: 123
  year: 2024
  end-page: 138
  ident: CR59
  article-title: Systematic analysis of DNA polymerases as therapeutic targets in pan-cancers
  publication-title: Biocell
  doi: 10.32604/biocell.2023.031568
– year: 2021
  ident: CR67
  article-title: The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): A systematic review and meta-analysis of randomized controlled trials
  publication-title: ESMO Open
  doi: 10.1016/j.esmoop.2021.100124
– volume: 33
  start-page: 1304
  year: 2022
  end-page: 1317
  ident: CR69
  article-title: Leveraging big data of immune checkpoint blockade response identifies novel potential targets
  publication-title: Ann. Oncol.
  doi: 10.1016/j.annonc.2022.08.084
– volume: 35
  start-page: 314
  year: 2017
  end-page: 316
  ident: CR38
  article-title: Toil enables reproducible, open source, big biomedical data analyses
  publication-title: Nat. Biotechnol.
  doi: 10.1038/nbt.3772
– volume: 1A
  start-page: 68
  year: 2015
  end-page: 77
  ident: CR36
  article-title: Review The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge
  publication-title: Współczesna Onkol
  doi: 10.5114/wo.2014.47136
– volume: 7
  start-page: 41404
  year: 2017
  ident: CR42
  article-title: Cholesterol synthetase DHCR24 induced by insulin aggravates cancer invasion and progesterone resistance in endometrial carcinoma
  publication-title: Sci. Rep.
  doi: 10.1038/srep41404
– volume: 77
  start-page: e108
  year: 2017
  end-page: e110
  ident: CR48
  article-title: TIMER: A web server for comprehensive analysis of tumor-infiltrating immunecells
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-17-0307
– volume: 550
  start-page: 204
  year: 2017
  end-page: 213
  ident: CR37
  article-title: Genetic effects on gene expression across human tissues
  publication-title: Nature
  doi: 10.1038/nature24277
– year: 2020
  ident: CR34
  article-title: Genome-wide identification of CpG island methylator phenotype related gene signature as a novel prognostic biomarker of gastric cancer
  publication-title: PeerJ
  doi: 10.7717/peerj.9624
– year: 2017
  ident: CR46
  article-title: Landscape of microsatellite instability across 39 cancer types
  publication-title: JCO Precis Oncol.
  doi: 10.1200/PO.17.00073
– volume: 5
  start-page: 1315
  year: 2010
  end-page: 1316
  ident: CR64
  article-title: Receiver operating characteristic curve in diagnostic test assessment
  publication-title: J. Thorac. Oncol.
  doi: 10.1097/JTO.0b013e3181ec173d
– volume: 48
  start-page: 812
  year: 2018
  end-page: 830.e14
  ident: CR50
  article-title: The immune landscape of cancer
  publication-title: Immunity
  doi: 10.1016/j.immuni.2018.03.023
– volume: 71
  start-page: 209
  year: 2021
  end-page: 249
  ident: CR1
  article-title: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
  publication-title: CA Cancer J. Clin.
  doi: 10.3322/caac.21660
– volume: 162
  start-page: 39
  year: 2017
  end-page: 48
  ident: CR11
  article-title: Clinical and molecular relevance of mutant-allele tumor heterogeneity in breast cancer
  publication-title: Breast Cancer Res. Treat.
  doi: 10.1007/s10549-017-4113-z
– volume: 13
  start-page: 1010879
  year: 2022
  ident: CR17
  article-title: Nucleophosmin 1 is a prognostic marker of gastrointestinal cancer and is associated with m6A and cuproptosis
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2022.1010879
– volume: 45
  start-page: 6116
  year: 2023
  end-page: 6139
  ident: CR41
  article-title: Small leucine-rich proteoglycan PODNL1 identified as a potential tumor matrix-mediated biomarker for prognosis and immunotherapy in a pan-cancer setting
  publication-title: Curr. Issues Mol. Biol.
  doi: 10.3390/cimb45070386
– volume: 4
  start-page: 2612
  year: 2013
  ident: CR51
  article-title: Inferring tumour purity and stromal and immune cell admixture from expression data
  publication-title: Nat. Commun.
  doi: 10.1038/ncomms3612
– volume: 21
  start-page: 4012
  year: 2020
  ident: CR53
  article-title: Gastric cancer: Epidemiology, risk factors, classification, genomic characteristics and treatment strategies
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms21114012
– volume: 22
  start-page: 260
  year: 2022
  ident: CR29
  article-title: Elevated expression of RAB3B plays important roles in chemoresistance and metastatic potential of hepatoma cells
  publication-title: BMC Cancer
  doi: 10.1186/s12885-022-09370-1
– volume: 12
  start-page: 17
  year: 2014
  ident: CR27
  article-title: miR-200b as a prognostic factor in breast cancer targets multiple members of RAB family
  publication-title: J. Transl. Med.
  doi: 10.1186/1479-5876-12-17
– volume: 499
  start-page: 214
  year: 2013
  end-page: 218
  ident: CR66
  article-title: Mutational heterogeneity in cancer and the search for new cancer-associated genes
  publication-title: Nature
  doi: 10.1038/nature12213
– volume: 20
  start-page: 131
  year: 2021
  ident: CR14
  article-title: Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: New findings and future perspectives
  publication-title: Mol. Cancer
  doi: 10.1186/s12943-021-01428-1
– volume: 2
  start-page: 879
  year: 2021
  end-page: 890
  ident: CR57
  article-title: Moving pan-cancer studies from basic research toward the clinic
  publication-title: Nat. Cancer
  doi: 10.1038/s43018-021-00250-4
– volume: 36
  start-page: 833
  year: 2022
  end-page: 849
  ident: CR5
  article-title: A pan-cancer analysis suggests an important role of in the immune response against stomach adenocarcinoma
  publication-title: J. Biol. Regul Homeost Agents
  doi: 10.23812/j.biol.regul.homeost.agents.20223604.94
– volume: 8
  start-page: 286
  year: 2007
  end-page: 298
  ident: CR12
  article-title: Cancer epigenomics: DNA methylomes and histone-modification maps
  publication-title: Nat. Rev. Genet.
  doi: 10.1038/nrg2005
– volume: 98
  start-page: 80
  year: 2017
  end-page: 85
  ident: CR32
  article-title: Exosomal proteins as prostate cancer biomarkers in urine: From mass spectrometry discovery to immunoassay-based validation
  publication-title: Eur. J. Pharm. Sci.
  doi: 10.1016/j.ejps.2016.09.023
– volume: 13
  start-page: 558
  year: 2021
  ident: CR10
  article-title: PD-L1, TMB, MSI, and other predictors of response to immune checkpoint inhibitors in biliary tract cancer
  publication-title: Cancers
  doi: 10.3390/cancers13030558
– year: 2013
  ident: CR45
  article-title: Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal
  publication-title: Sci. Signal.
  doi: 10.1126/scisignal.2004088
– volume: 40
  start-page: 245
  year: 2021
  end-page: 272
  ident: CR9
  article-title: An overview of genetic mutations and epigenetic signatures in the course of pancreatic cancer progression
  publication-title: Cancer Metast Rev.
  doi: 10.1007/s10555-020-09952-0
– volume: 31
  start-page: 859
  year: 2014
  ident: CR31
  article-title: miR-200b as a prognostic factor targets multiple members of RAB family in glioma
  publication-title: Med. Oncol.
  doi: 10.1007/s12032-014-0859-x
– volume: 18
  start-page: 310
  year: 2020
  ident: CR65
  article-title: Lower mutant-allele tumor heterogeneity is a biomarker in FGFR3-mutant bladder cancer for better prognosis
  publication-title: World J. Surg. Oncol.
  doi: 10.1186/s12957-020-02084-3
– volume: 8
  start-page: 909
  year: 2019
  ident: CR23
  article-title: Rab GTPases: Switching to human diseases
  publication-title: Cells
  doi: 10.3390/cells8080909
– year: 2015
  ident: CR40
  article-title: 2015 Tissue-based map of the human proteome
  publication-title: Science
  doi: 10.1126/science.1260419
– volume: 54
  start-page: 859
  year: 2021
  end-page: 874
  ident: CR3
  article-title: Chemokines and the immune response to cancer
  publication-title: Immunity
  doi: 10.1016/j.immuni.2021.01.012
– volume: 122
  start-page: 1295
  year: 2021
  end-page: 1301
  ident: CR24
  article-title: Rab3 proteins and cancer: Exit strategies
  publication-title: J. Cell. Biochem.
  doi: 10.1002/jcb.29948
– volume: 37
  start-page: 2193
  year: 2016
  end-page: 2207
  ident: CR30
  article-title: Combined analysis identifies six genes correlated with augmented malignancy from non-small cell to small cell lung cancer
  publication-title: Tumor Biol.
  doi: 10.1007/s13277-015-3938-5
– volume: 32
  start-page: 399
  year: 2012
  end-page: 414
  ident: CR26
  article-title: Integration of regulatory networks by NKX3-1 promotes androgen-dependent prostate cancer survival
  publication-title: Mol. Cell. Biol.
  doi: 10.1128/MCB.05958-11
– volume: 2
  start-page: 401
  year: 2012
  end-page: 404
  ident: CR44
  article-title: The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-12-0095
– volume: 38
  start-page: 2361
  year: 2024
  end-page: 2380
  ident: CR60
  article-title: CKS2 and its interacting network induce tumor progression with adverse effects on patients’ survival in a pan-cancer model
  publication-title: J. Biol. Regul Homeost Agents
  doi: 10.23812/j.biol.regul.homeost.agents.20243803.186
– volume: 47
  start-page: 351
  year: 2022
  end-page: 366
  ident: CR6
  article-title: A pan-cancer analysis of the biological function and clinical value of BTLA in tumors
  publication-title: Biocell
  doi: 10.32604/biocell.2023.025157
– year: 2021
  ident: CR18
  article-title: NPM1 Is a prognostic biomarker involved in immune infiltration of lung adenocarcinoma and associated With m6A modification and glycolysis
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2021.724741
– volume: 236
  start-page: 719
  year: 1997
  end-page: 722
  ident: CR28
  article-title: Differential expression of rab3 isoforms during differentiation of pancreatic acinar cell Line AR42J
  publication-title: Biochem. Biophys. Res. Commun.
  doi: 10.1006/bbrc.1997.7039
– volume: 17
  start-page: 515
  year: 2019
  end-page: 521
  ident: CR8
  article-title: Germline and somatic mutations in prostate cancer for the clinician
  publication-title: J. Natl. Compr. Cancer Netw.
  doi: 10.6004/jnccn.2019.7307
– volume: 47
  start-page: 1003
  year: 2023
  end-page: 1019
  ident: CR58
  article-title: Prognostic prediction and expression validation of NSD3 in pan-cancer analyses
  publication-title: Biocell
  doi: 10.32604/biocell.2023.027209
– volume: 28
  start-page: 1597
  year: 2021
  end-page: 1613.e7
  ident: CR70
  article-title: CD276 expression enables squamous cell carcinoma stem cells to evade immune surveillance
  publication-title: Cell Stem Cell
  doi: 10.1016/j.stem.2021.04.011
– volume: 19
  start-page: 649
  year: 2017
  end-page: 658
  ident: CR47
  article-title: UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses
  publication-title: Neoplasia
  doi: 10.1016/j.neo.2017.05.002
– volume: 110
  start-page: 3622
  year: 2019
  end-page: 3629
  ident: CR56
  article-title: Experimental identification of cancer driver alterations in the era of pan-cancer genomics
  publication-title: Cancer Sci.
  doi: 10.1111/cas.14210
– volume: 27
  start-page: 989
  year: 2021
  end-page: 995
  ident: CR25
  article-title: Expression of Rab3b in human glioma: Influence on cell proliferation and apoptosis
  publication-title: Curr. Pharm. Des.
  doi: 10.2174/1381612826666200917145228
– year: 2022
  ident: CR39
  article-title: Abstract 3912: cProSite: A web based interactive platform for on-line proteomics and phosphoproteomics data analysis
  publication-title: Cancer Res
  doi: 10.1158/1538-7445.AM2022-3912
– year: 2022
  ident: CR55
  article-title: Multi-omics analysis: Paving the path toward achieving precision medicine in cancer treatment and immuno-oncology
  publication-title: Front Mol. Biosci.
  doi: 10.3389/fmolb.2022.962743
– volume: 15
  start-page: 1685
  year: 2023
  ident: CR35
  article-title: Small extracellular vesicles (sEVs) biogenesis molecular players are associated with clinical outcome of colorectal cancer patients
  publication-title: Cancers
  doi: 10.3390/cancers15061685
– volume: 10
  start-page: 513
  year: 2009
  end-page: 525
  ident: CR61
  article-title: Rab GTPases as coordinators of vesicle traffic
  publication-title: Nat. Rev. Mol. Cell Biol.
  doi: 10.1038/nrm2728
– year: 2020
  ident: CR62
  article-title: Genome-wide analysis of the expression of circular RNA full-length transcripts and construction of the circRNA-miRNA-mRNA network in cervical cancer
  publication-title: Front Cell Dev. Biol.
  doi: 10.3389/fcell.2020.603516
– volume: 37
  start-page: 637
  year: 2023
  end-page: 646
  ident: CR7
  article-title: A pan-cancer analysis of deubiquitinating enzyme ubiquitin-specific protease 9X as a prognostic and immunological biomarker in human tumors
  publication-title: J. Biol. Reg. Homeos Agent
  doi: 10.23812/j.biol.regul.homeost.agents.20233702.64
– volume: 50
  start-page: 1
  year: 2018
  end-page: 11
  ident: CR20
  article-title: Immune checkpoint inhibitors: recent progress and potential biomarkers
  publication-title: Exp. Mol. Med.
  doi: 10.1038/s12276-018-0191-1
– volume: 13
  start-page: 1097015
  year: 2023
  ident: CR22
  article-title: ImmuneScore of eight-gene signature predicts prognosis and survival in patients with endometrial cancer
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2023.1097015
– volume: 173
  start-page: 291
  year: 2018
  ident: 60581_CR2
  publication-title: Cell
  doi: 10.1016/j.cell.2018.03.022
– volume: 54
  start-page: 859
  year: 2021
  ident: 60581_CR3
  publication-title: Immunity
  doi: 10.1016/j.immuni.2021.01.012
– volume: 13
  start-page: 558
  year: 2021
  ident: 60581_CR10
  publication-title: Cancers
  doi: 10.3390/cancers13030558
– volume: 12
  start-page: 17
  year: 2014
  ident: 60581_CR27
  publication-title: J. Transl. Med.
  doi: 10.1186/1479-5876-12-17
– volume: 2
  start-page: 401
  year: 2012
  ident: 60581_CR44
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-12-0095
– year: 2013
  ident: 60581_CR45
  publication-title: Sci. Signal.
  doi: 10.1126/scisignal.2004088
– year: 2020
  ident: 60581_CR34
  publication-title: PeerJ
  doi: 10.7717/peerj.9624
– volume: 50
  start-page: 1
  year: 2018
  ident: 60581_CR20
  publication-title: Exp. Mol. Med.
  doi: 10.1038/s12276-018-0191-1
– volume: 19
  start-page: 649
  year: 2017
  ident: 60581_CR47
  publication-title: Neoplasia
  doi: 10.1016/j.neo.2017.05.002
– volume: 162
  start-page: 39
  year: 2017
  ident: 60581_CR11
  publication-title: Breast Cancer Res. Treat.
  doi: 10.1007/s10549-017-4113-z
– volume: 28
  start-page: 1597
  year: 2021
  ident: 60581_CR70
  publication-title: Cell Stem Cell
  doi: 10.1016/j.stem.2021.04.011
– volume: 40
  start-page: 245
  year: 2021
  ident: 60581_CR9
  publication-title: Cancer Metast Rev.
  doi: 10.1007/s10555-020-09952-0
– volume: 32
  start-page: 399
  year: 2012
  ident: 60581_CR26
  publication-title: Mol. Cell. Biol.
  doi: 10.1128/MCB.05958-11
– volume: 71
  start-page: 209
  year: 2021
  ident: 60581_CR1
  publication-title: CA Cancer J. Clin.
  doi: 10.3322/caac.21660
– volume: 18
  start-page: 310
  year: 2020
  ident: 60581_CR65
  publication-title: World J. Surg. Oncol.
  doi: 10.1186/s12957-020-02084-3
– volume: 37
  start-page: 2193
  year: 2016
  ident: 60581_CR30
  publication-title: Tumor Biol.
  doi: 10.1007/s13277-015-3938-5
– volume: 550
  start-page: 204
  year: 2017
  ident: 60581_CR37
  publication-title: Nature
  doi: 10.1038/nature24277
– volume: 47
  start-page: 351
  year: 2022
  ident: 60581_CR6
  publication-title: Biocell
  doi: 10.32604/biocell.2023.025157
– year: 2022
  ident: 60581_CR33
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2022.798531
– year: 2015
  ident: 60581_CR40
  publication-title: Science
  doi: 10.1126/science.1260419
– volume: 14
  start-page: 1058627
  year: 2023
  ident: 60581_CR4
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2023.1058627
– year: 2021
  ident: 60581_CR18
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2021.724741
– volume: 38
  start-page: 2361
  year: 2024
  ident: 60581_CR60
  publication-title: J. Biol. Regul Homeost Agents
  doi: 10.23812/j.biol.regul.homeost.agents.20243803.186
– volume: 17
  start-page: 515
  year: 2019
  ident: 60581_CR8
  publication-title: J. Natl. Compr. Cancer Netw.
  doi: 10.6004/jnccn.2019.7307
– volume: 10
  start-page: 9579
  year: 2020
  ident: 60581_CR21
  publication-title: Theranostics
  doi: 10.7150/thno.48954
– year: 2021
  ident: 60581_CR67
  publication-title: ESMO Open
  doi: 10.1016/j.esmoop.2021.100124
– year: 2016
  ident: 60581_CR13
  publication-title: Cold Spring Harbor Perspect Biol.
  doi: 10.1101/cshperspect.a019505
– volume: 27
  start-page: 989
  year: 2021
  ident: 60581_CR25
  publication-title: Curr. Pharm. Des.
  doi: 10.2174/1381612826666200917145228
– volume: 48
  start-page: 812
  year: 2018
  ident: 60581_CR50
  publication-title: Immunity
  doi: 10.1016/j.immuni.2018.03.023
– year: 2017
  ident: 60581_CR46
  publication-title: JCO Precis Oncol.
  doi: 10.1200/PO.17.00073
– volume: 77
  start-page: 412
  year: 2018
  ident: 60581_CR68
  publication-title: Proc. Nutr. Soc.
  doi: 10.1017/S0029665118000150
– volume: 35
  start-page: 314
  year: 2017
  ident: 60581_CR38
  publication-title: Nat. Biotechnol.
  doi: 10.1038/nbt.3772
– volume: 10
  start-page: 513
  year: 2009
  ident: 60581_CR61
  publication-title: Nat. Rev. Mol. Cell Biol.
  doi: 10.1038/nrm2728
– volume: 5
  start-page: 1315
  year: 2010
  ident: 60581_CR64
  publication-title: J. Thorac. Oncol.
  doi: 10.1097/JTO.0b013e3181ec173d
– volume: 1A
  start-page: 68
  year: 2015
  ident: 60581_CR36
  publication-title: Współczesna Onkol
  doi: 10.5114/wo.2014.47136
– volume: 16
  start-page: 275
  year: 2016
  ident: 60581_CR19
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc.2016.36
– volume: 15
  start-page: 1685
  year: 2023
  ident: 60581_CR35
  publication-title: Cancers
  doi: 10.3390/cancers15061685
– volume: 10
  start-page: 1839
  year: 2021
  ident: 60581_CR52
  publication-title: Cancer Med.
  doi: 10.1002/cam4.3647
– year: 2020
  ident: 60581_CR62
  publication-title: Front Cell Dev. Biol.
  doi: 10.3389/fcell.2020.603516
– volume: 2
  start-page: 879
  year: 2021
  ident: 60581_CR57
  publication-title: Nat. Cancer
  doi: 10.1038/s43018-021-00250-4
– volume: 47
  start-page: 1003
  year: 2023
  ident: 60581_CR58
  publication-title: Biocell
  doi: 10.32604/biocell.2023.027209
– volume: 33
  start-page: 1304
  year: 2022
  ident: 60581_CR69
  publication-title: Ann. Oncol.
  doi: 10.1016/j.annonc.2022.08.084
– volume: 7
  start-page: 41404
  year: 2017
  ident: 60581_CR42
  publication-title: Sci. Rep.
  doi: 10.1038/srep41404
– volume: 77
  start-page: e108
  year: 2017
  ident: 60581_CR48
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-17-0307
– volume: 31
  start-page: 859
  year: 2014
  ident: 60581_CR31
  publication-title: Med. Oncol.
  doi: 10.1007/s12032-014-0859-x
– volume: 13
  start-page: 348
  year: 2016
  ident: 60581_CR54
  publication-title: Nat. Rev. Clin. Oncol.
  doi: 10.1038/nrclinonc.2016.15
– volume: 110
  start-page: 3622
  year: 2019
  ident: 60581_CR56
  publication-title: Cancer Sci.
  doi: 10.1111/cas.14210
– volume: 45
  start-page: 6116
  year: 2023
  ident: 60581_CR41
  publication-title: Curr. Issues Mol. Biol.
  doi: 10.3390/cimb45070386
– year: 2022
  ident: 60581_CR55
  publication-title: Front Mol. Biosci.
  doi: 10.3389/fmolb.2022.962743
– volume: 98
  start-page: 80
  year: 2017
  ident: 60581_CR32
  publication-title: Eur. J. Pharm. Sci.
  doi: 10.1016/j.ejps.2016.09.023
– volume: 48
  start-page: 123
  year: 2024
  ident: 60581_CR59
  publication-title: Biocell
  doi: 10.32604/biocell.2023.031568
– volume: 160
  start-page: 26
  year: 2023
  ident: 60581_CR43
  publication-title: Hereditas
  doi: 10.1186/s41065-023-00290-z
– volume: 499
  start-page: 214
  year: 2013
  ident: 60581_CR66
  publication-title: Nature
  doi: 10.1038/nature12213
– volume: 236
  start-page: 719
  year: 1997
  ident: 60581_CR28
  publication-title: Biochem. Biophys. Res. Commun.
  doi: 10.1006/bbrc.1997.7039
– volume: 24
  start-page: 729
  year: 2022
  ident: 60581_CR16
  publication-title: Oncologie
  doi: 10.32604/oncologie.2022.026118
– volume: 122
  start-page: 1295
  year: 2021
  ident: 60581_CR24
  publication-title: J. Cell. Biochem.
  doi: 10.1002/jcb.29948
– volume: 21
  start-page: 4012
  year: 2020
  ident: 60581_CR53
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms21114012
– volume: 8
  start-page: 286
  year: 2007
  ident: 60581_CR12
  publication-title: Nat. Rev. Genet.
  doi: 10.1038/nrg2005
– year: 2021
  ident: 60581_CR49
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2021.687975
– volume: 10
  start-page: 223
  year: 2021
  ident: 60581_CR15
  publication-title: Cells
  doi: 10.3390/cells10020223
– volume: 20
  start-page: 131
  year: 2021
  ident: 60581_CR14
  publication-title: Mol. Cancer
  doi: 10.1186/s12943-021-01428-1
– volume: 22
  start-page: 260
  year: 2022
  ident: 60581_CR29
  publication-title: BMC Cancer
  doi: 10.1186/s12885-022-09370-1
– year: 2022
  ident: 60581_CR39
  publication-title: Cancer Res
  doi: 10.1158/1538-7445.AM2022-3912
– volume: 8
  start-page: 909
  year: 2019
  ident: 60581_CR23
  publication-title: Cells
  doi: 10.3390/cells8080909
– volume: 13
  start-page: 1097015
  year: 2023
  ident: 60581_CR22
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2023.1097015
– volume: 37
  start-page: 637
  year: 2023
  ident: 60581_CR7
  publication-title: J. Biol. Reg. Homeos Agent
  doi: 10.23812/j.biol.regul.homeost.agents.20233702.64
– year: 2018
  ident: 60581_CR63
  publication-title: Phys. Med. Biol.
  doi: 10.1088/1361-6560/aab4b1
– volume: 36
  start-page: 833
  year: 2022
  ident: 60581_CR5
  publication-title: J. Biol. Regul Homeost Agents
  doi: 10.23812/j.biol.regul.homeost.agents.20223604.94
– volume: 13
  start-page: 1010879
  year: 2022
  ident: 60581_CR17
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2022.1010879
– volume: 4
  start-page: 2612
  year: 2013
  ident: 60581_CR51
  publication-title: Nat. Commun.
  doi: 10.1038/ncomms3612
SSID ssj0000529419
Score 2.4496198
Snippet RAB3B is essential for the transportation and secretion within cells. Its increased expression is linked to the development and progression of various...
Abstract RAB3B is essential for the transportation and secretion within cells. Its increased expression is linked to the development and progression of various...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 9881
SubjectTerms 631/67/1857
631/67/2329
631/67/327
631/67/580
631/67/69
Bioinformatics
Biomarkers, Tumor - genetics
Cancer
Carcinogenesis
Computational Biology - methods
Diagnosis
DNA Methylation
DNA microarrays
Gene Expression Regulation, Neoplastic
Genomes
Genotypes
Heterogeneity
Humanities and Social Sciences
Humans
Immune infiltration
Malignancy
Metastases
Microenvironments
Microsatellite instability
Molecular modelling
multidisciplinary
Mutation
Neoplasms - diagnosis
Neoplasms - genetics
Neoplasms - immunology
Neoplasms - pathology
Pan-cancer
Prognosis
rab3 GTP-Binding Proteins - genetics
rab3 GTP-Binding Proteins - metabolism
RAB3B
Science
Science (multidisciplinary)
Tumor Microenvironment - genetics
Tumor Microenvironment - immunology
Tumors
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LixQxEA6ysOBFdNdH6yoRvDnNdvqZHHfEZVlQRFzYW0jSFXbATcs8YPwf_mCrkp5xxufF63RCh1RV11dTVV8x9goxiG07cLmXTYsBigf8DjrIhe-lxK-mAUv_Q757315c1ZfXzfXOqC-qCUv0wOniTk0DyqqycOh3azDKFi0oUJ3yqihdH5lA0eftBFOJ1btUtVBjl0xRydMFeirqJivrnDKBIl_veaJI2P87lPlrseRPGdPoiM7vs3sjguRn6eQP2B0IR-wwzZT8esy-fTAhdyTLOTcj4wgnnibUM-5oFkeqfuNjhRb_eDatphzWY0VswF09X65uhzm_oVqZAVUMEKtP-Ix6SYDfUg3fToPcJO6gQq8w0MtmgW_KFHk6yOIhuzp_--nNRT6OXshdU4tlrqilFRoCa9ba3le9qn3TOQxnhbSdd4YM2RsLiG8UtJVtiFXGd7borbd19YgdhCHAE8bR_zvAKLFDLFoXxhrVOlzVKttbB95lTGzEoN3IS07jMT7rmB-vpE6i0yg6HUWn1xl7vd3zJbFy_HX1lKS7XUmM2vEH1DM96pn-l55l7GSjG3o084WuYt5UYMyasZfbx2iglHUxAYZVWkOTgKTI2OOkStuTVLKVEhF4xuSeku0ddf9JmN1EEnBBsTyi04xNNvr441x_voun_-MunrG7JRlSTKqdsIPlfAXPEZst7Ytoht8BHGA5gw
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagCIkL4k2gICNxY6Mmm5d9Ql1EVSGBEKLS3izbGdOVWqfsQ9r-j_5gZhwnZXn0mthaZ2fG_sbzzQxjbxGDmLoBmzpR1eigOMB90EKau1YI3DU1GLqH_PylPj4pP82rebxwW0Va5bAnho267SzdkR8UIUSVo3vw_uJnSl2jKLoaW2jcZneodBlRupp5M96xUBSrzGXMlckKcbDC84pyyqZlSvHAPN3unEehbP-_sObflMk_4qbhODp6wO5HHMkPe8E_ZLfAP2J3-86Sl4_Z1VftU0sSXXId645wqtaE2sYtdeToOXA88rT4t8NZMeOwjbxYj7Navt6cd0t-SoyZDhUNELFP-IIySoCfE5PvtzS5SZhBdC_f0Y8tPB_IirxfyOoJOzn6-P3DcRobMKS2KvN1KimxFSqCbMaY1hWtLF3VWHRqc2EaZzWZs9MGEOVIqAtTUW0Z15isNc6UxVO25zsPzxlHFGABfcUGEWmZaaNlbXFULU1rLDibsHwQg7KxOjk1yThTIUpeCNWLTqHoVBCd2ibs3Tjnoq_NcePoGUl3HEl1tcODbvlDRTNVugJp5DSzOLsELU1WgwTZSCezqW3LhO0PuqGisa_UtWom7M34Gs2UYi_aQ7fpx1A_IJEn7FmvSuNKClELgTg8YWJHyXaWuvvGL05DKfCcPHrEqAmbDPp4va7__xcvbv6Ml-zelEwkBM322d56uYFXiL3W5nUwsF_zCjDY
  priority: 102
  providerName: ProQuest
– databaseName: Springer Nature OA Free Journals
  dbid: C6C
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1ZaxRBEC5CRPBFjOeYRFrwzR2ce7ofs0tCEBQRA3lrunuqzYKZkT0g_g9_sFU9h65GwdedKqbYqur-auoCeEUYxFY1utjLsqIAxSOdgw7j1DdS0qlp0PJ3yHfvq_OL4u1lebkH2dgLE4r2w0jLcEyP1WFv1nTRcDNYVsScyEtjwo13eHQ7W_WiWkzfVThzVaRq6I9JcnkL684dFEb134Yv_yyT_C1XGq6gswdwf8CO4qSX9gD2sH0Id_ttkt8ewfcPpo0da3ElzDBrRPCEJrIw4XgLR1_3JobaLPHxZJ7PBd4MtbAtcTVis73uVuKKq2Q6Mi4klD4TS-4iQXHN1Xu_tMbNAgeXeLUdv2zZirFAUfSCrB_Dxdnpp8V5PCxdiF1ZpJtYcTMrlgzTrLWNzxtV-LJ2FMim0tbeGXZhbywSslFY5bbkeTK-tkljvS3yJ7Dfdi0-A0E3v0OKD2tCoUVirFGVI6pK2cY69C6CdFSDdsNEcl6M8UWHzHguda86TarTQXX6JoLXE8_Xfh7HP6nnrN2Jkmdphx-61Wc92JY2JSqrssQRd4FG2aRChapWXiWZa4oIjkbb0IODr3UeMqYpRasRvJwek2tyvsW02G17Gt4BJNMInvamNEmSy0pKwt4RyB0j2xF190m7vArjv1OO4gmXRjAb7fGnXH__L57_H_kh3MvYZULi7Aj2N6stHhP-2tgXweF-ADCvLyA
  priority: 102
  providerName: Springer Nature
Title Pan-cancer analysis reveals correlation between RAB3B expression and tumor heterogeneity, immune microenvironment, and prognosis in multiple cancers
URI https://link.springer.com/article/10.1038/s41598-024-60581-x
https://www.ncbi.nlm.nih.gov/pubmed/38688977
https://www.proquest.com/docview/3049081899
https://www.proquest.com/docview/3049720481
https://pubmed.ncbi.nlm.nih.gov/PMC11061125
https://doaj.org/article/a5e9b920c1594ea9b06e9e979f902cd4
Volume 14
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3da9swED-6lsFexr7nrgsa7G3xFn9LD2MkoaUEWkq3QN6MJEtroLVXJ4H0_9gfvDvZzpYtG-wpYEuO0N1Zv_Pd_Q7gLWIQlWZG-5YnKToo1uB7UBs_sAXn-NaURtF3yLPz9HQaT2bJbA-6dkftBi52unbUT2paX79f3959QoP_2JSM8w8LPISoUCyMfQryBT5iygM8mTIy1LMW7jdc36GIXa8PImH3EUyEbR3N7sdsnVWO0n8XDv0znfK3mKo7qk4ewcMWY7JhoxSPYc-UT-B-03Xy7il8v5Clr0naNZMtJwkjJifcEaapW0eTH8faHC52ORxFI2bWbc5sibMKtlzdVDW7omyaCpXQIJrvszlVmxh2Q1l-v5TQ9d0MSgUrK_qzecm6REbWLGTxDKYnx1_Gp37bnMHXSRwsfUFFryYhOKeUKmxUiNgmmUaHN-Aqs1qSqVupDCIgYdJIJcQ7YzM1KJRVcfQc9suqNC-BIULQBv3IDNFqPJBKilTjqFSoQmljtQdBJ4Zct8zl1EDjOncR9IjnjehyFF3uRJevPXi3mfOt4e345-gRSXczkji33YWq_pq3JpzLxAglwoHG2bGRQg1SI4zIhBWDUBexB0edbuSdHueRi6wG6NV68GZzG02Y4jKyNNWqGUO9gnjgwYtGlTYriXjKOWJ0D_iWkm0tdftOOb9yNOEBefuIXz3od_r4c11_34vD_9q5V_AgJItx8bUj2F_WK_MaYdpS9eBeNst6cDAcTj5P8Hd0fH5xiVfH6bjnPn30nHX-AAL5P_8
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1ZbxMxEB6VVIi-IG4WChgJnsiqe6_9gFADrVLaRlXVSn0za69NI7W7JYdI_we_g9_IzF4lHH3ra9ZOvJnP4288F8Ab5CAqSY12LY8TNFCsQT2ojevbnHPUmplRdA-5P0qGx9Hnk_hkBX62uTAUVtnqxEpR56WmO_KNsHJR-WgefLj45lLXKPKuti00aljsmsvvaLJN3-98Qvm-DYLtraOPQ7fpKuDqOPJnrqBsTRMTD1FK5TbMRWTjVKOl5nOVWp0RRm2mDB7dwiShiqlgik2VlyurohC_9xasRiGaMj1YHWyNDg67Wx3ym0W-aLJzvJBvTPGEpCy2IHLJA-m7i6UTsGoU8C92-3eQ5h-e2uoA3L4HdxvmyjZrqN2HFVM8gNt1L8vLh_DjICtcTRiasKypdMKoPhTim2nqAVJH3bEmMowdbg7CATOLJhK3wFk5m83Pywk7pRidEqFt0EboszHlsBh2TrGDvyXm9asZFGBWlPRj44K14ZGsXsj0ERzfiHAeQ68oC_MUGPIObdA6TZEDR16mMpFoHJUIlSttrHbAb8UgdVMPndpynMnKLx9yWYtOouhkJTq5cOBdN-eirgZy7egBSbcbSZW8qw_KyVfZKAaZxUYoEXgaZ0cmE8pLjDAiFVZ4gc4jB9ZbbMhGvUzl1WZw4HX3GBUDeXuywpTzegx1IOK-A09qKHUrCXnCOTJ_B_gSyJaWuvykGJ9Wxcd9ukNAVuxAv8Xj1br-_188u_41XsGd4dH-ntzbGe0-h7WAtkvlsluH3mwyNy-Q-c3Uy2a7Mfhy0zv8Fw1tb30
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VIhAXxJtAASPBiY0279gHhLqUVUuhqhCV9ubGjk1XapN2H2L7P_g1_DpmnGTL8uit18ROnMzDM55vZgBeoQ2istxo3_I0QwfFGtSD2vihLTlHrVkYReeQn_ey7YPk4ygdrcHPLheGYJWdTnSKuqw1nZH3YxeiCtE96NsWFrG_NXx3euZTBymKtHbtNBoW2TXn39F9m77d2UJav46i4Yev77f9tsOAr9MknPmCMjdNSjaJUqq0cSkSm-YavbaQq9zqgvjVFsrgNi5MFquUiqfYXAWlsiqJ8bnX4HoepyHJWD7Kl-c7FEFLQtHm6QQx709xr6R8tijxKRYZ-ouVvdC1DPiXnfs3XPOPmK3bCod34HZrw7LNhunuwpqp7sGNpqvl-X34sV9UviZumrCirXnCqFIUcjrT1A2kwd-xFiPGvmwO4gEzixaTW-Gsks3mJ_WEHRFap0YmN-gt9NiYslkMOyEU4W8pej03g6BmVU0vG1esA0qyZiHTB3BwJaR5COtVXZnHwNAC0Qb91Byt4SQoVCEyjaMyoUqljdUehB0ZpG4ro1ODjmPpIvQxlw3pJJJOOtLJhQdvlnNOm7ogl44eEHWXI6mmt7tQT77JVkXIIjVCiSjQODsxhVBBZoQRubAiiHSZeLDR8YZsFc1UXoiFBy-Xt1FFUNynqEw9b8ZQLyIeevCoYaXlSmKecY4-gAd8hclWlrp6pxofuTLkIZ0moH3sQa_jx4t1_f9fPLn8M17ATZRr-Wlnb_cp3IpIWlzsbgPWZ5O5eYYm4Ew9d7LG4PCqhfsX2GtyTQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pan-cancer+analysis+reveals+correlation+between+RAB3B+expression+and+tumor+heterogeneity%2C+immune+microenvironment%2C+and+prognosis+in+multiple+cancers&rft.jtitle=Scientific+reports&rft.au=Liu%2C+Xu-Sheng&rft.au=Chen%2C+Ya-Lan&rft.au=Chen%2C+Yu-Xuan&rft.au=Wu%2C+Rui-Min&rft.date=2024-04-30&rft.issn=2045-2322&rft.eissn=2045-2322&rft.volume=14&rft.issue=1&rft_id=info:doi/10.1038%2Fs41598-024-60581-x&rft.externalDBID=n%2Fa&rft.externalDocID=10_1038_s41598_024_60581_x
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon